Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)
NCT07654062 on ClinicalTrials.gov · last registry update 2026-06-17
An unusually large phase 4: 150 participants, more than double the 72 typical for the stage. Due to report June 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Proportion of Participants Achieving Normal Glucose Regulation (NGR) at Week 24. Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- mazdutide
- Sponsor
- Shandong Provincial Hospital
- Sponsor type
- Other Gov
- Enrollment
- 150
- Started
- 2026-07
- Primary completion
- 2028-06 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Proportion of Participants Achieving Normal Glucose Regulation (NGR) at Week 24
Conditions studied
Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance (Prediabetes)
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.